Medivation Reports First Quarter 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Medivation Reports First Quarter 2015 Financial Results

Leerink Partners Reit OP Rating Following Medivation (MDVN) 1Q Results

May 8, 2015 9:45 AM EDT

Leerink Partners maintains an Outperform rating on Medivation, Inc. (NASDAQ: MDVN), with their price target set at $128. Leerink believes that the demand for Xtandi appears to be solid, and expects a continued uptake of Xtandi over the rest of the year. MDVN reported US Xtandi sales were $224M in 1Q15. While this was in the... More

Medivation (MDVN) PT Lifted at UBS Despite Q1 'Miss'

May 8, 2015 9:40 AM EDT

UBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Medivation (NASDAQ: MDVN) to $142.00 (from $130.00) despite a miss on US Xtandi sales by $14m. The firm remain encouraged by the results since only nominal double-digit growth is required to beat 2015... More

Medivation (MDVN) Misses Q1 EPS by 10c

May 7, 2015 4:17 PM EDT

Medivation (NASDAQ: MDVN) reported Q1 EPS of $0.17, $0.10 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $127.8 million versus the consensus estimate of $149 million.

U.S. net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $224.0 million for the quarter (+80% vs. prior year). On its February 25, 2015 earnings call, Medivation stated its... More